Factors Consumers Often Consider When Evaluating Telehealth GLP-1 Platforms Rather than presenting a subjective assessment, this section outlines the factors that publicly available consumer guidance and healthcare resources suggest are worth considering when evaluating any telehealth GLP-1 program
Liraglutide, semaglutide and tirzepatide are incretin-based therapies currently approved by FDA for the management of obesity, while triple GIPR/GCGR/GLP-1R agonist retatrutide (LY3437943), the cagrilintide/semaglutide (CagriSema) 2.4 mg combination, high-dose oral semaglutide, and oral orforglipron are in advanced stages of development
Prioritize lean proteins (chicken, fish, lentils, tofu) to prevent muscle loss during weight loss
Among firms offering health benefits, 16% believe that their employees level of concern over the affordability of cost sharing is high, 29% believe the level of concern is moderate, 28% believe the level of concern is low, 20% believe the level of concern is none, and 7% do not know the level of concern [Figure 13.22]
Inflammatory and oxidative stress markers in post-traumatic stress disorder: a systematic review and meta-analysis
[7] Ye Z, et al
